Evidence map›Paper›PMID 38617236›Full record

ArticlebioRxiv : the preprint server for biology2024

Human Saposin B Ligand Binding and Presentation to α-Galactosidase A.

Thomas K Sawyer, Efecan Aral, James V Staros, Cedric E Bobst, Scott C Garman

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Thomas K SawyerDepartment of Biochemistry & Molecular Biology, Institute of Applied Life Sciences, University of Massachusetts, Amherst, Massachusetts 01003, USA.ORCID 0000-0002-3600-210X
Efecan AralDepartment of Biochemistry & Molecular Biology, Institute of Applied Life Sciences, University of Massachusetts, Amherst, Massachusetts 01003, USA.ORCID 0000-0002-2039-5041
James V StarosDepartment of Biochemistry & Molecular Biology, Institute of Applied Life Sciences, University of Massachusetts, Amherst, Massachusetts 01003, USA.ORCID 0000-0003-0971-3800
Cedric E BobstMass Spectrometry Core Facility, Institute of Applied Life Sciences, University of Massachusetts, Amherst, Massachusetts 01003, USA.ORCID 0009-0001-2680-1100
Scott C GarmanDepartment of Biochemistry & Molecular Biology, Institute of Applied Life Sciences, University of Massachusetts, Amherst, Massachusetts 01003, USA.ORCID 0000-0001-9912-2670
University of Massachusetts Amherst · US

Funding

A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Aina E. Cohen, KEITH O HODGSON · 2020 to 2026
$43.3M
Structural Studies of Lysosomal Storage DiseasesR01DK076877 · NIDDK · UNIVERSITY OF MASSACHUSETTS AMHERST · PI GARMAN, SCOTT C. · 2007 to 2021
$4.3M
NIDDK NIH HHS R01 DK076877NIGMS NIH HHS P30 GM133894
6 · The paper itself

Abstract

Sphingolipid activator protein B (saposin B; SapB) is an essential activator of globotriaosylceramide (Gb3) catabolism by α-galactosidase A. However, the manner by which SapB stimulates α-galactosidase A activity remains unknown. To uncover the molecular mechanism of SapB presenting Gb3 to α-galactosidase A, we subjected the fluorescent substrate globotriaosylceramide-nitrobenzoxidazole (Gb3-NBD) to a series of biochemical and structural assays involving SapB. First, we showed that SapB stably binds Gb3-NBD using a fluorescence equilibrium binding assay, isolates Gb3-NBD from micelles, and facilitates α-galactosidase A cleavage of Gb3-NBD

Identifiers

PMID38617236
PMCPMC11014568
OpenAlexW4393985899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.